Fully automated immunoassay for cholesterol uptake capacity to assess high-density lipoprotein function and cardiovascular disease risk

• Published in: Scientific reports Vol. 13; no. 1; p. 1899
• Main Authors: Murakami, Katsuhiro, Harada, Amane, Toh, Ryuji, Kubo, Takuya, Miwa, Keiko, Kim, Jeeeun, Kiriyama, Maria, Iino, Takuya, Nishikawa, Youichi, Uno, Shin-Nosuke, Akatsuchi, Kohei, Nagao, Manabu, Ishida, Tatsuro, Hirata, Ken-ichi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 02.02.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/61/32; 692/53; Acyltransferase; Automation; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - diagnosis; Chemiluminescence; Cholesterol; Cholesterol, HDL; Coronary artery disease; Health risks; Heart diseases; High density lipoprotein; Humanities and Social Sciences; Humans; Immunoassay; Lecithin; Lipoproteins, HDL; multidisciplinary; N-Ethylmaleimide; Peroxidase; Reproducibility of Results; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-28953-x

High-density lipoprotein (HDL) cholesterol efflux capacity (CEC), which is a conventional metric of HDL function, has been associated with coronary heart disease risk. However, the CEC assay requires cultured cells and takes several days to perform. We previously established a cell-free assay to evaluate cholesterol uptake capacity (CUC) as a novel measure of HDL functionality and demonstrated its utility in coronary risk stratification. To apply this concept clinically, we developed a rapid and sensitive assay system based on a chemiluminescent magnetic particle immunoassay. The system is fully automated, providing high reproducibility. Measurement of CUC in serum is completed within 20 min per sample without HDL isolation, a notably higher throughput than that of the conventional CEC assay. CUC decreased with myeloperoxidase-mediated oxidation of HDL or in the presence of N -ethylmaleimide, an inhibitor of lecithin: cholesterol acyltransferase (LCAT), whereas CUC was enhanced by the addition of recombinant LCAT. Furthermore, CUC correlated with CEC even after being normalized by ApoA1 concentration and was significantly associated with the requirement for revascularization due to the recurrence of coronary lesions. Therefore, our new assay system shows potential for the accurate measurement of CUC in serum and permits assessing cardiovascular health.